SDF-1/CXCR4 signaling up-regulates survivin to regulate human sacral chondrosarcoma cell cycle and epithelial–mesenchymal transition via ERK and PI3K/AKT pathway

Medical Oncology

Volumn 32, Issue 1, 2015, Pages

  Yang, Peng ^a,b   Wang, Gang ^a   Huo, Hongjun ^b   Li, Qiang ^c   Zhao, Yan ^b   Liu, Yuanhang ^b,d  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b The Second Affiliated Hospital of Inner Mongolia Medical University   (China)

^c AFFILIATED HOSPITAL OF INNER MONGOLIA MEDICAL UNIVERSITY   (China)

^d Department of Pharmacy   (China)

Author keywords

Cell cycle; CXCR4; EMT; Sacral chondrosarcoma; Survivin

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; NERVE CELL ADHESION MOLECULE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE B; SMALL INTERFERING RNA; STROMAL CELL DERIVED FACTOR 1; SURVIVIN; TRANSCRIPTION FACTOR SNAIL; BIRC5 PROTEIN, HUMAN; CXCL12 PROTEIN, HUMAN; CXCR4 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN;

ADULT; ARTICLE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL FATE; CELL MEMBRANE; CHONDROSARCOMA; CHONDROSARCOMA CELL LINE; CONTROLLED STUDY; CYTOPLASM; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE; SACRAL CHONDROSARCOMA; SIGNAL TRANSDUCTION; UPREGULATION; AGED; BONE TUMOR; CELL CYCLE; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; SACRUM; WESTERN BLOTTING;

ADULT; AGED; BLOTTING, WESTERN; BONE NEOPLASMS; CELL CYCLE; CHEMOKINE CXCL12; CHONDROSARCOMA; EPITHELIAL-MESENCHYMAL TRANSITION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MIDDLE AGED; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, CXCR4; RNA INTERFERENCE; RNA, SMALL INTERFERING; SACRUM; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84920193051     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0377-x     Document Type: Article

References (27)

1. Randall RL, Bruckner J, Lloyd C, et al. Sacral resection and reconstruction for tumors and tumor-like conditions. Orthopedics. 2005;28:307–13.
2. Bergh P, Gunterberg B, Meis-Kindblom JM, et al. Prognostic factors and outcome of pelvic, sacral, and spinal chondrosarcomas: a center-based study of 69 cases. Cancer. 2001;91:1201–12.
3. Leone A, Costantini A, Guglielmi G, et al. Primary bone tumors and pseudotumors of the lumbosacral spine. Rays. 2000;25:89–103.
4. Rhomberg W, Eiter H, Böhler F, et al. Combined radiotherapy and razoxane in the treatment of chondrosarcomas and chordomas. Anticancer Res. 2006;26:2407–11.
5. Polyak K, Weinberg RA. Transition between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nature Rev Cancer. 2009;9:265–73.
6. Mani SA, Guo W, Liao MJ, et al. The epithelial–mesenchymal transition generates cells with properties of stem cells. Cell. 2008;16:704–15.
7. Nieto MA. Epithelial plasticity: a common theme in embryonic and cancer cells. Science. 2013;342:1234850.
8. Wheelock MJ, Shintani Y, Maeda M, et al. Cadherin switching. J Cell Sci. 2008;121:727–35.
9. Nurwidya F, Takahashi F, Murakami A, et al. Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer. Cancer Res Treat. 2012;44:151–6.
10. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial–mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7:131–42.
11. Gao D, Vahdat LT, Wong S, et al. Microenvironmental regulation of epithelial–mesenchymal transitions in cancer. Cancer Res. 2012;72:4883–9.
12. Dave B, Mittal V, Tan NM, et al. Epithelial–mesenchymal transition, cancer stem cells and treatment resistance. Breast Cancer Res. 2012;14:202.
13. Roy I, Evans DB, Dwinell MB. Chemokines and chemokine receptors: update on utility and challenges for the clinician. Surgery. 2014;155:961–73.
14. Yoshie O. Chemokine receptors as therapeutic targets. Nihon Rinsho Meneki Gakkai Kaishi. 2013;36:189–96.
15. Li W, Chen YQ, Shen YB, et al. HIF-1α knockdown by miRNA decreases survivin expression and inhibits A549 cell growth in vitro and in vivo. Int J Mol Med. 2013;32:271–80.
16. Skoufias DA, Mollinari C, Lacroix FB, et al. Human survivin is a kinetochore-associated passenger protein. J Cell Biol. 2000;151:1575–82.
17. Lladser A, Sanhueza C, Kiessling R, et al. Is survivin the potential Achilles’ heel of cancer? Adv Cancer Res. 2011;111:1–37.
18. Zuryń A, Litwiniec A, Gackowska L, et al. Expression of cyclin A, B1 and D1 after induction of cell cycle arrest in the Jurkat cell line exposed to doxorubicin. Cell Biol Int. 2012;36:1129–35.
19. Park WH, Seol JG, Kim ES, et al. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res. 2000;60:3065–71.
20. Biliran H Jr, Wang Y, Banerjee S, et al. Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line. Clin Cancer Res. 2005;11:6075–86.
21. Schwindt TT, Forti FL, Juliano MA, et al. Arginine vasopressin inhibition of cyclin D1 gene expression blocks the cell cycle and cell proliferation in the mouse Y1 adrenocortical tumor cell line. Biochemistry. 2003;42:2116–21.
22. Payton M, Chung G, Yakowec P, et al. Discovery and evaluation of dual CDK1 and CDK2 inhibitors. Cancer Res. 2006;66:4299–308.
23. L’Italien L, Tanudji M, Russell L, et al. Unmasking the redundancy between Cdk1 and Cdk2 at G2 phase in human cancer cell lines. Cell Cycle. 2006;5:984–93.
24. Ahn SH, Jeong EH, Lee TG, et al. Gefitinib induces cytoplasmic translocation of the CDK inhibitor p27 and its binding to a cleaved intermediate of caspase 8 in non-small cell lung cancer cells. Cell Oncol (Dordr). 2014;37:377–86.
25. Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 2009;19:156–72.
26. Wendt MK, Allington TM, Schiemann WP. Mechanisms of the epithelial–mesenchymal transition by TGF-beta. Future Oncol. 2009;5:1145–68.
27. Miyazono K. Transforming growth factor-beta signaling in epithelial–mesenchymal transition and progression of cancer. Proc Jpn Acad Ser B Phys Biol Sci. 2009;85:314–23.